Nadine L de Boer1, Jan A W Hagemans2, Bob T A Schultze2, Alexandra R M Brandt-Kerkhof2, Eva V E Madsen2, Cornelis Verhoef2, Jacobus W A Burger3. 1. Department of Surgical Oncology, Erasmus MC Cancer Institute, Rotterdam, the Netherlands. Electronic address: n.deboer@erasmusmc.nl. 2. Department of Surgical Oncology, Erasmus MC Cancer Institute, Rotterdam, the Netherlands. 3. Department of Surgical Oncology, Erasmus MC Cancer Institute, Rotterdam, the Netherlands; Department of Surgery, Catharina Cancer Institute, Eindhoven, the Netherlands.
Abstract
INTRODUCTION: Patients with peritoneal carcinomatosis who do not have curative treatment options often develop acute obstructive symptoms and when conservative management fails, surgical treatment is the remaining option. However, palliative surgery is associated with high morbidity and mortality and the chance of success is unclear. The aim of this study was to evaluate outcomes of palliative surgery and to provide guidance for surgeons, medical oncologists and patients in their decision-making. METHODS: All consecutive patients who underwent palliative surgery for acute obstruction caused by peritoneal carcinomatosis between January 2005 and October 2017 where identified. RESULTS: In total 148 patients underwent surgery. Primary malignancy was colorectal cancer (28.4%), neuroendocrine tumor (20.3%), ovarian cancer (14.2%) or 'other' (37.2%). Median length of postoperative hospital stay was 16 days (IQR 9-24). More than half (58.1%) of the patients developed postoperative complications, 29.1% developed ≥2 complications. In-hospital mortality was 8.8%. Readmission (56.1%) and re-obstruction (35.0%) were common. Median overall survival was 119 days (IQR 48-420). Patients with a neuroendocrine tumor had a significantly better overall survival compared to other primary malignancies (p < 0.001). Patients who developed an obstruction during or within 6 months after treatment with chemotherapy had a worse overall survival (p < 0.001), compared to patients treated with chemotherapy longer than 6 months ago, or patients not treated with chemotherapy. CONCLUSION: Palliative surgery is associated with high rates of complications and readmission and re-obstruction are common. Comfort care is often a better option than surgery, especially in patients with disease progression under recent treatment with chemotherapy.
INTRODUCTION:Patients with peritoneal carcinomatosis who do not have curative treatment options often develop acute obstructive symptoms and when conservative management fails, surgical treatment is the remaining option. However, palliative surgery is associated with high morbidity and mortality and the chance of success is unclear. The aim of this study was to evaluate outcomes of palliative surgery and to provide guidance for surgeons, medical oncologists and patients in their decision-making. METHODS: All consecutive patients who underwent palliative surgery for acute obstruction caused by peritoneal carcinomatosis between January 2005 and October 2017 where identified. RESULTS: In total 148 patients underwent surgery. Primary malignancy was colorectal cancer (28.4%), neuroendocrine tumor (20.3%), ovarian cancer (14.2%) or 'other' (37.2%). Median length of postoperative hospital stay was 16 days (IQR 9-24). More than half (58.1%) of the patients developed postoperative complications, 29.1% developed ≥2 complications. In-hospital mortality was 8.8%. Readmission (56.1%) and re-obstruction (35.0%) were common. Median overall survival was 119 days (IQR 48-420). Patients with a neuroendocrine tumor had a significantly better overall survival compared to other primary malignancies (p < 0.001). Patients who developed an obstruction during or within 6 months after treatment with chemotherapy had a worse overall survival (p < 0.001), compared to patients treated with chemotherapy longer than 6 months ago, or patients not treated with chemotherapy. CONCLUSION: Palliative surgery is associated with high rates of complications and readmission and re-obstruction are common. Comfort care is often a better option than surgery, especially in patients with disease progression under recent treatment with chemotherapy.
Authors: Rachel A Pozzar; Andrea C Enzinger; Hanneke Poort; Ann Furey; Heidi Donovan; Meghan Orechia; Embree Thompson; Anna Tavormina; Anny T H R Fenton; Tim Jaung; Ilana M Braun; Andrea DeMarsh; Mary E Cooley; Alexi A Wright Journal: J Palliat Med Date: 2022-03-17 Impact factor: 2.947
Authors: Andrew S Miller; Kathryn Boyce; Benjamin Box; Matthew D Clarke; Sarah E Duff; Niamh M Foley; Richard J Guy; Lisa H Massey; George Ramsay; Dominic A J Slade; James A Stephenson; Phil J Tozer; Danette Wright Journal: Colorectal Dis Date: 2021-02 Impact factor: 3.917
Authors: Claudio Lodoli; Marcello Covino; Miriam Attalla El Halabieh; Francesco Santullo; Andrea Di Giorgio; Carlo Abatini; Stefano Rotolo; Elena Rodolfino; Francesco Giovinazzo; Anna Fagotti; Giovanni Scambia; Francesco Franceschi; Fabio Pacelli Journal: Front Surg Date: 2021-11-26
Authors: Jolene Si Min Wong; Sze Min Lek; Daniel Yan Zheng Lim; Claramae Shulyn Chia; Grace Hwei Ching Tan; Chin-Ann Johnny Ong; Melissa Ching Ching Teo Journal: Front Oncol Date: 2022-01-13 Impact factor: 6.244